Table 5 Adverse events grade⩾3 by lines of therapy (safety population)

From: Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

 

1 previous line of therapy

⩾ 2 previous lines of therapy

 

KRd

n=182

Rd

n=154

KRd

n=210

Rd

n=235

Grade⩾3 AEs occurring in⩾3% of patients in any subgroup (preferred terms), n (%)

Neutropenia

48 (26.4)

34 (22.1)

68 (32.4)

69 (29.4)

Anemia

31 (17.0)

30 (19.5)

39 (18.6)

37 (15.7)

Thrombocytopenia

28 (15.4)

18 (11.7)

37 (17.6)

30 (12.8)

Pneumonia

22 (12.1)

16 (10.4)

27 (12.9)

25 (10.6)

Hypophosphatemia

18 (9.9)

8 (5.2)

15 (7.1)

10 (4.3)

Hypokalemia

14 (7.7)

11 (7.1)

23 (11.0)

8 (3.4)

Fatigue

13 (7.1)

10 (6.5)

17 (8.1)

15 (6.4)

Hyperglycemia

11 (6.0)

10 (6.5)

9 (4.3)

8 (3.4)

Cataract

10 (5.5)

4 (2.6)

5 (2.4)

6 (2.6)

Pulmonary embolism

8 (4.4)

4 (2.6)

4 (1.9)

5 (2.1)

RTI

8 (4.4)

3 (1.9)

8 (3.8)

5 (2.1)

Asthenia

7 (3.8)

5 (3.2)

7 (3.3)

3 (1.3)

Hypertension

7 (3.8)

1 (0.6)

10 (4.8)

6 (2.6)

Hypocalcemia

7 (3.8)

3 (1.9)

6 (2.9)

3 (1.3)

Insomnia

7 (3.8)

4 (2.6)

4 (1.9)

7 (3.0)

Diarrhea

6 (3.3)

6 (3.9)

9 (4.3)

10 (4.3)

Leukopenia

6 (3.3)

5 (3.2)

6 (2.9)

11 (4.7)

Lymphopenia

6 (3.3)

3 (1.9)

5 (2.4)

5 (2.1)

Decreased platelet count

6 (3.3)

3 (1.9)

6 (2.9)

6 (2.6)

Rash

4 (2.2)

5 (3.2)

1 (0.5)

1 (0.4)

Decreased neutrophil count

4 (2.2)

1 (0.6)

8 (3.8)

10 (4.3)

Dyspnea

4 (2.2)

4 (2.6)

7 (3.3)

3 (1.3)

Syncope

3 (1.6)

2 (1.3)

2 (1.0)

8 (3.4)

AEs of interest (grouped terms), n (%)

 Cardiac failurea

6 (3.3)

3 (1.9)

9 (4.3)

4 (1.7)

 Ischemic heart diseaseb

9 (4.9)

2 (1.3)

4 (1.9)

6 (2.6)

 Acute renal failurec

6 (3.3)

5 (3.2)

7 (3.3)

7 (3.0)

  1. Abbreviations: AE, adverse event; KRd, carfilzomib, lenalidomide and dexamethasone; MI, myocardial infarction; Rd, lenalidomide and dexamethasone; RTI, respiratory tract infection.
  2. aIncluded: cardiac failure, congestive cardiac failure, pulmonary edema, hepatic congestion, cardiopulmonary failure, acute pulmonary edema, acute cardiac failure and right ventricular failure.
  3. bIncluded: angina pectoris, MI, acute MI, coronary artery occlusion, acute coronary syndrome, abnormal cardiac stress test, cardiomyopathy stress, unstable angina and coronary artery stenosis.
  4. cIncluded: acute renal failure, renal failure, renal impairment and azotemia.
Back to article page